Ferrante Karen Jean 4
4 · Cogent Biosciences, Inc. · Filed Jun 11, 2026
Research Summary
AI-generated summary of this filing
Cogent Biosciences Director Karen Ferrante Receives 17,901-Share Award
What Happened
Karen Ferrante, a director of Cogent Biosciences (COGT), was granted a stock option award on June 9, 2026 covering 17,901 shares. The filing records the acquisition price as $0.00 (derivative award), meaning no cash was paid at grant. This is a compensation award — not an open‑market purchase or sale.
Key Details
- Transaction date: 2026-06-09; filing date: 2026-06-11 (timely filing).
- Transaction type/code: Award/Grant (A) — derivative stock option covering 17,901 shares.
- Price: $0.00 recorded at acquisition in the filing; exercise price (if any) is not stated in the excerpt.
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Footnote (F1): The option vests in full upon the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Stockholders, subject to Ferrante’s continued service through that date.
Context
This is a typical board compensation grant that gives the director the right to acquire shares in the future if vesting and any exercise conditions are met. It does not represent an immediate purchase or sale of company stock. For full details (exercise price, total holdings, and any additional terms), consult the complete Form 4 filing or the company’s proxy/compensation disclosures.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-09+17,901→ 17,901 totalExercise: $31.98Exp: 2036-06-09→ Common Stock (17,901 underlying)
Footnotes (1)
- [F1]This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.